LDR | | 00000nmm u2200205 4500 |
001 | | 000000330119 |
005 | | 20241024151610 |
008 | | 181129s2017 ||| | | | eng d |
020 | |
▼a 9780355555387 |
035 | |
▼a (MiAaPQ)AAI10742639 |
035 | |
▼a (MiAaPQ)wustl:12408 |
040 | |
▼a MiAaPQ
▼c MiAaPQ
▼d 248032 |
049 | 1 |
▼f DP |
082 | 0 |
▼a 616 |
100 | 1 |
▼a Sutphen, Courtney. |
245 | 10 |
▼a Longitudinal Cerebrospinal Fluid Biomarkers of Alzheimer Disease: Movement Toward the Diagnosis, Prognosis and Staging of Disease. |
260 | |
▼a [S.l.] :
▼b Washington University in St. Louis.,
▼c 2017 |
260 | 1 |
▼a Ann Arbor :
▼b ProQuest Dissertations & Theses,
▼c 2017 |
300 | |
▼a 194 p. |
500 | |
▼a Source: Dissertation Abstracts International, Volume: 79-05(E), Section: B. |
500 | |
▼a Advisers: Anne M. Fagan |
502 | 1 |
▼a Thesis (Ph.D.)--Washington University in St. Louis, 2017. |
506 | |
▼a This item is not available from ProQuest Dissertations & Theses. |
520 | |
▼a Alzheimer's disease (AD) is a devastating neurodegenerative disease that slowly claims the memories and experiences that comprise the life experiences of individuals that suffer from the disease. Despite a continually accelerating pace of resear |
520 | |
▼a One important aspect of AD treatment is identification. It is now recognized that the disease begins more than a decade before the signature symptoms of cognitive impairment become apparent. Identifying individuals in this "preclinical" disease |
520 | |
▼a Biomarkers, indicators of normal biological or pathological processes that may be studied as a means to give individuals a disease diagnosis, prognosis, or theragnosis -- provided a treatment is available for the disease in question -- are of pa |
520 | |
▼a The current work begins with an overview of biomarker modalities used in AD |
520 | |
▼a The ACS cohort is comprised of middle-aged, cognitively normal individuals recruited on a volunteer basis from community dwelling participants with and without a family history of AD. The ADNI cohort is comprised of older individuals also recrui |
520 | |
▼a In both cohorts, it was found that CSF markers of amyloid plaques -- one of two required pathological hallmarks that indicate AD -- changed earlier than those of tau tangles, the second required pathological hallmark. |
520 | |
▼a Currently, examining biomarkers on a group-wide basis is the best way to get an accurate picture of biomarkers at baseline and followup lumbar punctures (LPs). As the goal is to be able to give individual people a diagnosis and prognosis of thei |
590 | |
▼a School code: 0252. |
650 | 4 |
▼a Neurosciences. |
690 | |
▼a 0317 |
710 | 20 |
▼a Washington University in St. Louis.
▼b Biology & Biomedical Sciences (Neurosciences). |
773 | 0 |
▼t Dissertation Abstracts International
▼g 79-05B(E). |
773 | |
▼t Dissertation Abstract International |
790 | |
▼a 0252 |
791 | |
▼a Ph.D. |
792 | |
▼a 2017 |
793 | |
▼a English |
856 | 40 |
▼u http://www.riss.kr/pdu/ddodLink.do?id=T14996798
▼n KERIS |
980 | |
▼a 201812
▼f 2019 |
990 | |
▼a 관리자
▼b 관리자 |